Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006;20(2):42-6.
doi: 10.1002/jcla.20102.

Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers

Affiliations

Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers

Kuo-Chien Tsao et al. J Clin Lab Anal. 2006.

Abstract

A total of 73,443 asymptomatic individuals were screened on a voluntary basis for cancer at Chang Gung Memorial Hospital in Taiwan using a panel of tumor markers, including alpha fetoprotein (AFP), CA 125, CA 15-3, CA 19-9, carcinoembryonic antigen (CEA), prostate specific antigen (PSA), chromogranin A (CgA), and squamous cell specific antigen (SCC). The results are derived from data collected from January 1998 to October 2003. A total of 210 cancers (approximately 0.3%) were detected, including cancers of the liver, lung, colon, prostate, stomach, pancreas, breast, cervix, ovary, and bladder. Of the tumor markers monitored, elevated CA 19-9, CEA, and CA 125 were the most frequently detected in a variety of cancers. It was surprising to find that many cancers were not detected by their dominant markers but by the elevation of tumor markers not recommended for monitoring their tumor activity. Screening with multiple circulating tumor markers provides improved sensitivity for cancer detection in asymptomatic individuals before they reach the fatal advanced stage. Screening with multiple tumor markers also allows cancers to be detected in the absence of their dominant markers. If we had not measured the multiple tumor markers, these cancers would have gone undetected.

PubMed Disclaimer

References

    1. Wu JT, Nakamura R. Human circulating tumor markers. Current concepts and clinical applications. Chicago: American Society of Clinical Pathologists Press, 1997.
    1. Catalona W, Smith DS, Ratliff TL, et al. Measurement of prostate‐specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991:324;1156–1161. - PubMed
    1. Wu JT. Expression of monoclonal antibody‐defined tumor markers in four carcinomas. Ann Clin Lab Sci 1989;19:17–26 - PubMed
    1. Wu T‐L, Chang CP‐Y, Tsao K‐C, Sun C‐F, Wu JT. Development of a microplate assay for serum chromogranin A (CgA): establishment of normal reference values and the detection of elevated CgA in carcinomas. J Clin Lab Anal 1999;13:312–319. - PMC - PubMed
    1. Wu JT, Astill ME, Liu GH, Stephenson RA. Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients. J Clin Lab Anal 1998;12:20–25. - PMC - PubMed

Publication types